IAN SMITH, Royal Marsden Hospital, London
REFERENCE: Lancet 369:29
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from the Herceptin Adjuvant (HERA) Study conducted among 3,000 women in Europe.
Confirmation of the life-extending benefits of trastuzumab adjuvant therapy for early breast cancer has been published recently in the Lancet. Ian Smith gave Peter Goodwin three-year follow up results from the Herceptin Adjuvant (HERA) Study conducted among 3,000 women in Europe.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
